Literature DB >> 31483681

Role of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis.

Nikos Xylourgidis1, Kisuk Min2, Farida Ahangari1, Guoying Yu1, Jose D Herazo-Maya1, Theodoros Karampitsakos3, Vassilis Aidinis4, Leonhard Binzenhöfer1, Demosthenes Bouros3, Anton M Bennett5, Naftali Kaminski1, Argyrios Tzouvelekis1,4.   

Abstract

Mitogen-activated protein kinase (MAPK) phosphatase 5 (MKP-5) is a member of the dual-specificity family of protein tyrosine phosphatases that negatively regulates p38 MAPK and the JNK. MKP-5-deficient mice exhibit improved muscle repair and reduced fibrosis in an animal model of muscular dystrophy. Here, we asked whether the effects of MKP-5 on muscle fibrosis extend to other tissues. Using a bleomycin-induced model of pulmonary fibrosis, we found that MKP-5-deficient mice were protected from the development of lung fibrosis, expressed reduced levels of hydroxyproline and fibrogenic genes, and displayed marked polarization towards an M1-macrophage phenotype. We showed that the profibrogenic effects of the transforming growth factor-β1 (TGF-β1) were inhibited in MKP-5-deficient lung fibroblasts. MKP-5-deficient fibroblasts exhibited enhanced p38 MAPK activity, impaired Smad3 phosphorylation, increased Smad7 levels, and decreased expression of fibrogenic genes. Myofibroblast differentiation was attenuated in MKP-5-deficient fibroblasts. Finally, we found that MKP-5 expression was increased in idiopathic pulmonary fibrosis (IPF)-derived lung fibroblasts but not in whole IPF lungs. These data suggest that MKP-5 plays an essential role in promoting lung fibrosis. Our results couple MKP-5 with the TGF-β1 signaling machinery and imply that MKP-5 inhibition may serve as a therapeutic target for human lung fibrosis.

Entities:  

Keywords:  MKP-5; fibroblast; homeostasis; kinase; phosphatase; pulmonary fibrosis

Mesh:

Substances:

Year:  2019        PMID: 31483681      PMCID: PMC6879900          DOI: 10.1152/ajplung.00264.2018

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  46 in total

1.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras.

Authors:  M Kretzschmar; J Doody; I Timokhina; J Massagué
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

Review 2.  Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis.

Authors:  Dean Sheppard
Journal:  Proc Am Thorac Soc       Date:  2006-07

3.  p38 kinase inhibitor approved for idiopathic pulmonary fibrosis.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2011-04       Impact factor: 54.908

4.  The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling.

Authors:  H Hayashi; S Abdollah; Y Qiu; J Cai; Y Y Xu; B W Grinnell; M A Richardson; J N Topper; M A Gimbrone; J L Wrana; D Falb
Journal:  Cell       Date:  1997-06-27       Impact factor: 41.582

Review 5.  Idiopathic pulmonary fibrosis: an update.

Authors:  Paolo Spagnolo; Nicola Sverzellati; Giulio Rossi; Alberto Cavazza; Argyris Tzouvelekis; Bruno Crestani; Carlo Vancheri
Journal:  Ann Med       Date:  2015-01-22       Impact factor: 4.709

6.  Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World".

Authors:  Argyris Tzouvelekis; Evangelos Bouros; Vasilios Tzilas; Demosthenes Bouros
Journal:  Respiration       Date:  2017-09-05       Impact factor: 3.580

Review 7.  Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.

Authors:  Delphine Javelaud; Alain Mauviel
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

8.  Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.

Authors:  A Nakao; M Afrakhte; A Morén; T Nakayama; J L Christian; R Heuchel; S Itoh; M Kawabata; N E Heldin; C H Heldin; P ten Dijke
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

9.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis.

Authors:  Hiroto Matsuoka; Toru Arai; Masahide Mori; Sho Goya; Hiroshi Kida; Hiroshi Morishita; Hiroshi Fujiwara; Isao Tachibana; Tadashi Osaki; Seiji Hayashi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-07       Impact factor: 5.464

View more
  6 in total

1.  MAP Kinase Phosphatase-5 Deficiency Protects Against Pressure Overload-Induced Cardiac Fibrosis.

Authors:  Chao Zhong; Kisuk Min; Zhiqiang Zhao; Cheng Zhang; Erhe Gao; Yan Huang; Xinbo Zhang; Margaret Baldini; Rajika Roy; Xiaofeng Yang; Walter J Koch; Anton M Bennett; Jun Yu
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 8.786

2.  Angiotensin II Induces Cardiac Edema and Hypertrophic Remodeling through Lymphatic-Dependent Mechanisms.

Authors:  Jie Bai; Liangqingqing Yin; Wei-Jia Yu; Yun-Long Zhang; Qiu-Yue Lin; Hui-Hua Li
Journal:  Oxid Med Cell Longev       Date:  2022-02-18       Impact factor: 6.543

Review 3.  Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Shengming Liu; Shanrui Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 4.  Pathophysiological Roles of Stress-Activated Protein Kinases in Pulmonary Fibrosis.

Authors:  Yoshitoshi Kasuya; Jun-Dal Kim; Masahiko Hatano; Koichiro Tatsumi; Shuichi Matsuda
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

5.  An allosteric site on MKP5 reveals a strategy for small-molecule inhibition.

Authors:  Zachary T K Gannam; Kisuk Min; Shanelle R Shillingford; Lei Zhang; James Herrington; Laura Abriola; Peter C Gareiss; Georgios Pantouris; Argyrios Tzouvelekis; Naftali Kaminski; Xinbo Zhang; Jun Yu; Haya Jamali; Jonathan A Ellman; Elias Lolis; Karen S Anderson; Anton M Bennett
Journal:  Sci Signal       Date:  2020-08-25       Impact factor: 9.517

6.  Pulmonary fibrosis: something old, something new…still waiting for a breakthrough.

Authors:  Carol Feghali-Bostwick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.